	US 12,006,340 B2
	Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
Adel Moussa, Burlington, MA (US); and Jean-Pierre Sommadossi, Boston, MA (US)
Assigned to Atea Pharmaceuticals, Inc., Boston, MA (US)
Filed by Atea Pharmaceuticals, Inc., Boston, MA (US)
Filed on Jan. 23, 2023, as Appl. No. 18/100,448.
Application 18/100,448 is a continuation of application No. 17/306,659, filed on May 3, 2021, abandoned.
Application 17/306,659 is a continuation of application No. 16/918,918, filed on Jul. 1, 2020, granted, now 10,894,804, issued on Jan. 19, 2021.
Application 16/918,918 is a continuation of application No. 16/687,136, filed on Nov. 18, 2019, granted, now 10,906,928, issued on Feb. 2, 2021.
Application 16/687,136 is a continuation of application No. 15/885,630, filed on Jan. 31, 2018, granted, now 10,519,186, issued on Dec. 31, 2019.
Claims priority of provisional application 62/575,248, filed on Oct. 20, 2017.
Claims priority of provisional application 62/488,366, filed on Apr. 21, 2017.
Claims priority of provisional application 62/469,912, filed on Mar. 10, 2017.
Claims priority of provisional application 62/453,437, filed on Feb. 1, 2017.
Prior Publication US 2024/0018179 A1, Jan. 18, 2024
Int. Cl. C07H 19/207 (2006.01); A61K 9/20 (2006.01); A61K 31/7076 (2006.01); A61K 31/708 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01); C07H 19/20 (2006.01)

CPC C07H 19/20 (2013.01) [A61K 9/20 (2013.01); A61K 9/2054 (2013.01); A61K 31/7076 (2013.01); A61K 31/708 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01); C07B 2200/13 (2013.01)]

15 Claims

1. A process for preparing Compound 2 comprising the steps of:

(a) dissolving Compound 1 in an organic solvent;

(b) adding a sufficient amount of H₂SO₄/solvent mixture to the solution of Compound 1 from step (a) to form a hemisulfate salt (Compound 2);

(d) filtering the Compound 2 precipitate and washing with an organic solvent or a mixture of organic solvents.